For tube 2 of the EF AML/MDS panel, the most discriminating markers identified in PC1 were CD64 (18%), FSC (14%), and SSC (12%), whereas PC2 included HLA-DR (43%) and CD34 (21%), resulting in the clear distinction between t(15;17) AML blasts, normal monocyte-committed HPCs, and blasts from other AML categories. The gene discussed is CD34; the disease is acute myeloid leukemia.